BRÈVE

sur Biophytis (EPA:ALBPS)

Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at Up to €108 Million

Biophytis has signed an exclusive licensing agreement with Blanver for BIO101 in Latin America, potentially worth up to €108 million. Blanver will oversee the registration, marketing, and commercialization of the drug.

The agreement includes initial payments and future milestone payments, alongside double-digit royalties on sales. Targets include obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy.

Both companies will also collaborate on manufacturing and clinical development. Blanver's existing network will cover distribution across Latin America, extending beyond Brazil to countries like Mexico, Argentina, and Colombia.

This partnership aims to expand BIO101's reach, supported by positive clinical outcomes in various indications. It aligns with Biophytis' strategic goals, especially for obesity treatments, in a rapidly growing pharmaceutical market.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Biophytis